GlassScriptPhysician profile
Alexander Goldberg
NPI 1952371734
$11,599.10
in general payments reported to CMS, 2019-2025
56 companies · $1,719 in 2025
The $1,719 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,550 · 2020: $1,403 · 2021: $2,319 · 2022: $1,419 · 2023: $1,490 · 2024: $1,700 · 2025: $1,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,835 · Education: $73.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,834.72 |
| Education | $73.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,689.46 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,645.00 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $962.28 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $829.59 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $614.30 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $604.07 | 2019-2024 | Xifaxan |
| Esperion Therapeutics, INC. | $402.99 | 2021-2025 | Nexletol, Nexlizet |
| Janssen Pharmaceuticals, INC | $389.32 | 2019-2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $301.34 | 2022-2025 | |
| Pfizer INC. | $300.35 | 2019-2025 | |
| Amarin Pharma, INC. | $283.60 | 2019-2022 | |
| Antares Pharma, INC. | $281.52 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Orexo US, INC. | $272.91 | 2019-2021 | |
| Amgen INC. | $240.18 | 2019-2025 | Repatha, Otezla, Repatha |
| Indivior INC. | $231.92 | 2019-2024 | Sublocade |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.